Guides
4 pages in this section, most recently updated September 4, 2026.
- 01
How the GLP-1 class works: one receptor, then two, then three
The physiology behind every entry on this site: what GLP-1 does, why the native hormone is useless as a drug, the three engineering tricks that made it last, what GIP, glucagon and amylin add, and how peptides differ from the new small molecule.
Updated September 4, 2026
- 02
Approved, investigational, discontinued, compounded: what each status means
How to read the status line on every entry: what an FDA approval is and is not, what phase 3 published means for availability, why a discontinued drug is still approved, and why compounded semaglutide and tirzepatide sit outside all of it.
Updated September 4, 2026
- 03
GLP-1 approval timeline, 2005 to 2026
Every FDA approval and major label supplement for GLP-1 and GIP/GLP-1 agents in date order, from Byetta in April 2005 to Mounjaro's cardiovascular indication in August 2026, each with its Drugs@FDA application number.
Updated September 4, 2026
- 04
Glossary: the terms used on every GLP-1 entry
Plain definitions of the words that recur across this site: incretin, GLP-1, GIP, glucagon, amylin, receptor agonist, dual and triple agonist, peptide and small molecule, half-life, DPP-4, albumin binding, boxed warning, NDA and BLA, supplement, accelerated approval, 503A and 503B, and the trial vocabulary.
Updated September 4, 2026